FDA grants orphan drug designation to tesevatinib for the treatment of EGFR mutated NSLCL

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tesevatinib, an oral tyrosine kinase inhibitor, for the treatment of non-small cell lung cancer (NSCLC) with epithelial growth factor receptor (EGFR)-activating...

from # All Medicine by Alexandros G. Sfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2hGF9nI
via IFTTT